Cargando…

Paliperidone extended-release: does it have a place in antipsychotic therapy?

Paliperidone (9-hydroxy-risperidone), the active metabolite of risperidone, was approved for treating schizophrenia worldwide in 2006 as paliperidone extended-release (PER), and became the first second-generation antipsychotic specifically licensed for treating schizoaffective disorder in 2009. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gahr, Maximilian, Kölle, Markus A, Schönfeldt-Lecuona, Carlos, Lepping, Peter, Freudenmann, Roland W
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063117/ https://www.ncbi.nlm.nih.gov/pubmed/21448450 http://dx.doi.org/10.2147/DDDT.S17266

Ejemplares similares

From benzodiazepine to pregabalin dependence: Different agents, similar problems
por: Gahr, Maximilian, et al.
Publicado: (2015)

Successful treatment of schizophrenia with melperone augmentation in a patient with phenotypic CYP2D6 ultrarapid metabolization: a case report
por: Gahr, Maximilian, et al.
Publicado: (2012)

Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany
por: Elsayed, Mohamed, et al.
Publicado: (2020)

Tomophobia, the phobic fear caused by an invasive medical procedure - an emerging anxiety disorder: a case report
por: Schmid, Markus, et al.
Publicado: (2009)

The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release
por: Lee, Hee-Won, et al.
Publicado: (2013)

Depressive Disorder With Panic Attacks After Replacement of an Intrauterine Device Containing Levonorgestrel: A Case Report
por: Zeiss, René, et al.
Publicado: (2020)

Autoimmune polyglandular syndrome type 2 and recurrent depression
por: Elsayed, Mohamed, et al.
Publicado: (2023)

Non-Invasive Brain Stimulation in Conversion (Functional) Weakness and Paralysis: A Systematic Review and Future Perspectives
por: Schönfeldt-Lecuona, Carlos, et al.
Publicado: (2016)

Retinal single-layer analysis with optical coherence tomography (OCT) in schizophrenia spectrum disorder
por: Kregel, T., et al.
Publicado: (2022)

Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement
por: Gahr, Maximilian, et al.
Publicado: (2017)

Risk of Bleeding Associated With Antidepressants: Impact of Causality Assessment and Competition Bias on Signal Detection
por: Zeiss, René, et al.
Publicado: (2021)

Corrigendum: Risk of Bleeding Associated With Antidepressants: Impact of Causality Assessment and Competition Bias on Signal Detection
por: Zeiss, René, et al.
Publicado: (2021)

Treatment of bipolar mania with paliperidone extended-release
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions
por: Elsayed, Mohamed, et al.
Publicado: (2019)

Risk of Bleeding Associated with Antidepressant Drugs: The Competitive Impact of Antithrombotics in Quantitative Signal Detection
por: Zeiss, René, et al.
Publicado: (2021)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
por: Yang, Fu De, et al.
Publicado: (2017)

Role of paliperidone extended-release in treatment of schizoaffective disorder
por: Canuso, Carla M, et al.
Publicado: (2010)

The role of paliperidone extended release for the treatment of bipolar disorder
por: Marino, Jehan, et al.
Publicado: (2012)

Effects of paliperidone extended release on the symptoms and functioning of schizophrenia
por: Huang, Min-Wei, et al.
Publicado: (2012)

Incidence of inpatient cases with mental disorders due to use of cannabinoids in Germany: a nationwide evaluation
por: Gahr, Maximilian, et al.
Publicado: (2022)

Lithium Therapy Associated With Renal and Upper and Lower Urinary Tract Tumors: Results From a Retrospective Single-Center Analysis
por: Gahr, Maximilian, et al.
Publicado: (2019)

Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER)
por: Jung, Seung-Ho, et al.
Publicado: (2013)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study
por: Geitona, Maria, et al.
Publicado: (2008)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study
por: Geitona, Maria, et al.
Publicado: (2009)

Paliperidone extended release for the treatment of pediatric and adolescent patients with Tourette's disorder
por: Yamamuro, Kazuhiko, et al.
Publicado: (2014)

Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
por: Spina, Edoardo, et al.
Publicado: (2011)

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
por: Jariyavilas, Apichat, et al.
Publicado: (2017)

Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia
por: Helldin, Lars, et al.
Publicado: (2015)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2008)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
por: Nakagawa, Ryoko, et al.
Publicado: (2015)

Development of Obsessive-Compulsive Symptoms Following Abrupt Discontinuation of Venlafaxine
por: Gahr, Maximilian, et al.
Publicado: (2020)

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
por: Cai, Shangli, et al.
Publicado: (2015)

Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
por: Markowitz, Michael, et al.
Publicado: (2013)

Correction: Depression, mitochondrial bioenergetics, and electroconvulsive therapy: a new approach towards personalized medicine in psychiatric treatment - a short review and current perspective
por: Karabatsiakis, Alexander, et al.
Publicado: (2020)

Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
por: Patel, R., et al.
Publicado: (2018)

An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
por: Si, TianMei, et al.
Publicado: (2015)

Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
por: Levitan, Bennett, et al.
Publicado: (2016)

Randomized Controlled Trial of Paliperidone Extended Release Versus Risperidone for the Treatment of Methamphetamine-Associated Psychosis in Chinese Patients
por: Wang, Gang, et al.
Publicado: (2020)

Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
por: Brown, Brianne, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a9r6s3hk7ov2p9st2lfq8jpvmg